Montelukast |
montelukast sodium; Singulair |
Article: Montelukast
| Image:Singulair.jpg | |
| Montelukast | |
| Systematic (IUPAC) name | |
| 2-[1-[[(1R)-1-[3-[2-(7-chloroquinolin-2-yl)ethenyl] phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl] sulfanylmethyl]cyclopropyl]acetic acid | |
| Identifiers | |
| CAS number | 158966-92-8 |
| ATC code | R03DC03 |
| PubChem | 60951 |
| DrugBank | APRD00434 |
| Chemical data | |
| Formula | C35H36NClO3S |
| Mol. weight | 586.184 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99% |
| Metabolism | Hepatic (CYP3A4 and CYP2C9-mediated) |
| Half life | 2.7-5.5 hours |
| Excretion | Biliary |
| Therapeutic considerations | |
| Pregnancy cat. | B (U.S.), B1 (Au) |
| Legal status | ℞-only (U.S.), POM (UK), S4 (Au) |
| Routes | Oral |
Montelukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is not useful for the treatment of acute asthma attacks, so patients should also be supplied with rescue medication, such as an albuterol inhaler. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1, thus inhibiting bronchoconstriction.
Montelukast is marketed by Merck & Co. with the brand name Singulair®. It is available as oral tablets, chewable tablets, and oral granules.

Not Signed In -


